Pros | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | 1/8 | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 7 Years | ||
Fund Size | 4027 Cr | 6104 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.91% | 1.04% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 39 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.44%) Divi's Laboratories Ltd (7.21%) Max Healthcare Institute Ltd Ordinary Shares (6.5%) Cipla Ltd (4.63%) Lonza Group Ltd ADR (4.09%) | Sun Pharmaceuticals Industries Ltd (11.69%) Dr Reddy's Laboratories Ltd (8.85%) Divi's Laboratories Ltd (8.13%) Cipla Ltd (7.54%) Aurobindo Pharma Ltd (5.71%) | ||
No of Sectors | 3 | 3 | ||
Top 3 Sectors | Health (93.89%) Basic Materials (6.11%) Government (2.58%) | Health (96.53%) Basic Materials (2.35%) Financial Services (1.11%) | ||
Equity % | 97.62% | 95.89% | ||
Debt % | 0.07% | - | ||
P/E | 44.9 | 32.47 | ||
P/B | 6.42 | 4.4 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -0.43% | -0.53% | ||
3-Month Return | 3.74% | 4.36% | ||
6-Month Return | 11.97% | 17.88% | ||
1-Year Return | 6.12% | 4.69% | ||
3-Year Return | 28.01% | 29.71% | ||
5-Year Return | 22.28% | 22.63% |
Sharpe | 1.36 | 1.31 | ||
Alpha | 4.73 | 4.41 | ||
Beta | 0.84 | 0.94 | ||
Standard Deviation | 13.92 | 15.52 | ||
Information Ratio | 0.72 | 1.42 |
Description | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Tanmaya Desai | Dharmesh Kakkad,Sharmila D’mello |